Amicus Therapeutics (FOLD) Shares are Down -3.01%

Amicus Therapeutics (FOLD) has risen sharply, recording gains of 9.63% in the past 4 weeks. However, the stock has corrected -3.01% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 10.22% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 2.05% and the 50-Day Moving Average is 6.27%.The 200 Day SMA reached 4.37%


Amicus Therapeutics (NASDAQ:FOLD): After opening at $7.12, the stock dipped to an intraday low of $6.99 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $7.52 and the buying power remained strong till the end. The stock closed at $7.4 for the day, a gain of 4.67% for the day session. The total traded volume was 1,839,436. The stocks close on the previous trading day was $7.4.

Amicus Therapeutics (FOLD) : 7 investment research analysts covering Amicus Therapeutics (FOLD) have an average price target of $13.29 for the near short term. The highest target price given by the Brokerage Firm to the stock is $19 and the lowest target is $9 for the short term. Analysts expect the variance to be within $3.4 of the average price.

Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Companys lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Companys development programs also include ERTs for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Companys programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as ERT products for Fabry disease, Pompe disease and MPS I.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *